Ken Griffin Acurx Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,000 shares of ACXP stock, worth $36,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,000
Previous 7,800
105.13%
Holding current value
$36,000
Previous $29,000
34.48%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
30Shares Held
1.25MCall Options Held
16.1KPut Options Held
33.8K-
Vanguard Group Inc Valley Forge, PA492KShares$1.11 Million0.0% of portfolio
-
Prospect Financial Services LLC Melville, NY273KShares$613,9120.55% of portfolio
-
Geode Capital Management, LLC Boston, MA116KShares$261,7920.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ57.3KShares$128,8120.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$97,7980.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $26M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...